Investigational Study of Delayed Release Metformin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is suspended. It plans to enroll 675 participants.

Also called NCT04854512

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 675 participants (planned count) (from the registry)
Sponsor
Anji Pharma (from the registry)
Registry
  • NCT NCT04854512
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Brazil, Bulgaria, Canada, Czechia, Hungary, Poland, Spain (from the registry)
Registry status
  • Suspended (from the registry)

Technical summary

Registry record NCT04854512. Randomized; double masking; primary purpose treatment. Start 2021-05-18 (actual); primary completion 2023-12-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Investigational Study of Delayed Release Metformin
Acronym
DREAM-T2D
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Metformin DR
Intervention (Drug)
Metformin IR
Intervention (Drug)
Metformin DR Placebo
Intervention (Drug)
Metformin IR placebo
Lead sponsor
Anji Pharma (class: industry)

Record details

Record id
cardio:ct-nct04854512
Content hash
efbc125bf2dfbebefadd1b1bedccecc4bd7d39b9828b46a01b2c407ceff20eb5